XPO1 and hematopoietic and lymphoid cell neoplasm: To test whether the XPO1 occupancy assay can predict sensitivity of cancer cells to selinexor treatment, it was performed on a panel of cell lines from many different types of both solid and hematological cancers each with various levels of selinexor sensitivity (by MTT, IC50 values).